Cintas vs Science Applications Intl
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Cintas and Science Applications Intl side by side, using each one’s latest annual report. Here is what stands out:
- Cintas is the larger business, with $11.3B of revenue in fiscal 2026 against $7.3B for Science Applications Intl, about 1.6 times as much.
- Cintas grew revenue faster (8.9%, against −2.9%).
- Cintas kept more of each dollar of sales as operating profit (23.1% operating margin, against 7.2%).
- Cintas turned more of its sales into free cash flow (16.7% FCF margin, against 8.0%).
- Cintas earned a higher return on the capital invested in it (31.7%, against 12.8%).
- Investors pay more for each dollar of Cintas’s earnings: a P/E of 44.6x against 17.3x for Science Applications Intl.
Who comes out ahead
Of the 11 measures where higher (or lower) is clearly better, how many each company leads.
Cintas
CTAS
10/11
Revenue growth5-year growthGross marginOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDA
Science Applications Intl
SAIC
1/11
Share count change
Side by side
Best in the row
| Latest fiscal year | CTAS FY26 | SAIC FY26 |
|---|---|---|
| Size | ||
| Market cap | $91.3B | $6.4B |
| Revenue | $11.3B | $7.3B |
| Free cash flow | $1.9B | $577M |
| Net income | $2.0B | $358M |
| Growth | ||
| Revenue growth | 8.9% | −2.9% |
| 5-year growth | 9.6% | 0.6% |
| Share count change | −1.0% | −7.9% |
| Profitability | ||
| Gross margin | 50.7% | 12.0% |
| Operating margin | 23.1% | 7.2% |
| Net margin | 17.8% | 4.9% |
| FCF margin | 16.7% | 8.0% |
| Return on capital | 31.7% | 12.8% |
| Return on equity | 40.7% | 23.3% |
| Balance sheet | ||
| Net debt | $1.1B | $2.3B |
| Net debt / EBITDA | 0.4x | 4.2x |
| Dividends and buybacks | $1.7B | $515M |
| Valuation & quality | ||
| P/E | 44.6x | 17.3x |
| Piotroski F-score | 8 | 7 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.